Therapeutic effect of Jianpi Huazhi Formula on acute ulcerative colitis mice and its influence on inflammatory factors

ZHUANG Ruifei; XU Yi; JIN Xi; XU Yanjie; CHEN Liang

doi:10.16306/j.1008-861x.2024.02.008

您当前的位置：

首页 >

文章列表页 >

Therapeutic effect of Jianpi Huazhi Formula on acute ulcerative colitis mice and its influence on inflammatory factors

Special column on anti-inflammatory of traditional Chinese medicine | 更新时间：2024-04-15

- Therapeutic effect of Jianpi Huazhi Formula on acute ulcerative colitis mice and its influence on inflammatory factors
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 38, Issue 2, Pages: 52-60(2024)
- 作者机构：
  
  南京中医药大学南通附属医院（江苏　南通　226001）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2024.02.008
  CLC：
- Published：25 March 2024，
  
  Received：15 November 2022，
  
  Revised：20 June 2023，
扫描看全文
庄瑞斐,徐逸,金玺等.健脾化滞方对急性溃疡性结肠炎小鼠的治疗作用及对炎症因子的影响[J].上海中医药大学学报,2024,38(02):52-60.

ZHUANG Ruifei,XU Yi,JIN Xi,et al.Therapeutic effect of Jianpi Huazhi Formula on acute ulcerative colitis mice and its influence on inflammatory factors[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):52-60.
庄瑞斐,徐逸,金玺等.健脾化滞方对急性溃疡性结肠炎小鼠的治疗作用及对炎症因子的影响[J].上海中医药大学学报,2024,38(02):52-60. DOI： 10.16306/j.1008-861x.2024.02.008.

ZHUANG Ruifei,XU Yi,JIN Xi,et al.Therapeutic effect of Jianpi Huazhi Formula on acute ulcerative colitis mice and its influence on inflammatory factors[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):52-60. DOI： 10.16306/j.1008-861x.2024.02.008.

摘要

目的

探讨健脾化滞方对急性溃疡性结肠炎（UC）模型小鼠的治疗作用，并基于小鼠血清及结肠组织炎症因子表达水平探讨其作用机制。

方法

将76只健康雄性C57小鼠随机分为正常组、模型组、美沙拉秦组及健脾化滞方低、中、高剂量组。通过饮用3%葡聚糖硫酸钠（DSS）溶液建立急性UC小鼠模型，健脾化滞方低、中、高剂量组小鼠分别灌胃给予145.8、291.5、583.0 g/L健脾化滞方溶液，美沙拉秦组小鼠灌胃给予10 g/L美沙拉秦溶液。观察各组小鼠症状，进行疾病活动指数（DAI）评分，苏木素-伊红（HE）染色观察小鼠结肠组织病理变化，并采用速率法和终点法检测小鼠血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、直接胆红素（DBil）、总胆红素（TBil）、白蛋白（ALB）、碱性磷酸酶（ALP）、γ-谷氨酰转肽酶（γ-GT）、总胆汁酸（TBA）、肌酐（Cre）、尿酸（UA）、尿素氮（BUN）水平，采用酶联免疫吸附实验（ELISA）测定小鼠血清与结肠组织中白介素（IL）-6、肿瘤坏死因子-α（TNF-α）、IL-10的水平。

结果

健脾化滞方可有效改善急性UC小鼠便血、腹泻等临床症状，改善其体质量的下降及小鼠结肠长度的缩减，并能降低小鼠DAI评分（

0.05），减轻结肠组织病理炎症损伤程度，降低血清和结肠组织中促炎性细胞因子IL-6、TNF-α的表达水平（

0.05，

0.01），提高抗炎因子IL-10的表达水平（

0.05，

0.01）。

结论

健脾化滞方对急性UC小鼠有较好的治疗作用，其作用机制可能为修复UC小鼠结肠黏膜局部损伤，调节血清及结肠组织炎症因子水平。

Abstract

Objective： To study the therapeutic effect of Jianpi Huazhi Formula （JHF） on acute ulcerative colitis （UC） model mice， and explore its mechanism of action based on the expression levels of inflammatory factors in serum and colon tissue of mice.

Methods

Seventy-six healthy male C57 mice were randomly divided into normal group， model group， mesalazine group， and low， medium， and high dose JHF groups. An acute UC mouse model was established by drinking 3% dextran sulfate sodium （DSS） solution. The low， medium， and high dose JHF groups were orally administered with 145.8， 291.5， 583.0 g/L JHF solution respectively， while the mesalazine group was orally administered with 10 g/L mesalazine solution. The symptoms of mice in each group were observed， the disease activity index （DAI） was scored， and the pathological changes of colon tissue were observed by hematoxylin-eosin （HE） staining. Serum levels of alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， direct bilirubin （DBil）， total bilirubin （TBil）， albumin （ALB）， alkaline phosphatase （ALP）， γ-glutamyl transpeptidase （γ-GT）， total bile acid （TBA）， creatinine （Cre）， uric acid （UA） and blood urea nitrogen （BUN） were measured by rate method and endpoint method. The levels of interleukin （IL）-6， tumor necrosis factor-α （TNF-α） and IL-10 in serum and colon tissue of mice were determined by enzyme-linked immunosorbent assay （ELISA）.

Results

JHF could effectively improve clinical symptoms such as bloody stools and diarrhea in acute UC mice， improve body mass loss and colon length reduction of mice， reduce DAI score of mice （

0.05）， alleviate the degree of pathological inflammation damage in colon tissue， reduce the expression levels of pro-inflammatory cytokines IL-6 and TNF-α， and increase the expression level of anti-inflammatory factor IL-10 （

0.05，

0.01）.

Conclusion

JHF has a good therapeutic effect on acute UC mice， and its mechanism of action may be to repair local damage to the colon mucosa of UC mice， regulate the levels of inflammatory factors in serum and colon tissue.

关键词

健脾化滞方溃疡性结肠炎白介素-6肿瘤坏死因子-α白介素-10

Keywords

Jianpi Huazhi Formulaulcerative colitisIL-6TNF-αIL-10

references

TRIPATHI K，FEUERSTEIN J D. New developments in ulcerative colitis：latest evidence on management，treatment，and maintenance ［J］. Drugs Context， 2019， 8： 212572.

UNGARO R，MEHANDRU S，ALLEN P B，et al. Ulcerative colitis［J］. Lancet， 2017， 389（10080）： 1756-1770.

NG S C. Emerging Trends of Inflammatory Bowel Disease in Asia［J］. Gastroenterol hepatol （NY）， 2016， 12（3）： 193-196.

ZHAO J，NG S C，LEI Y，et al. First prospective， population-based inflammatory bowel disease incidence study in mainland of China： the emergence of "western" disease［J］. Inflamm Bowel Dis， 2013， 19（9）： 839-1845.

LI Q M，WANG Y H，LYU F F，et al. Comparative study of rat models with ulcerative colitis and ulcerative colitis plus damp-heat syndrome［J］. Acta Lab Anim Sci Sin， 2021， 9（3）： 354-363.

UNGARO R，MEHANDRU S，ALLEN P B，et al. Ulcerative co-litis［J］. Lancet， 2017， 389（10080）： 1756 -1770．

ISKANDAR H N，DHERE T，FARRAYE F A. Ulcerativecolitis：update on medical managemen［J］. Curr Gastroenterol Rep， 2015， 17（11）： 44-53．

吴开春，梁洁，冉志华，等．炎症性肠病诊断与治疗的共识意见（2018年·北京）［J］. 中国实用内科杂志， 2018， 38（9）： 796-813.

WU K C，LIANG J，RAN Z H，et al. Consensus on diagnosis and treatment of Inflammatory bowel disease （2018·Beijing）［J］. Chinese Journal of Practical Internal Medicine， 2018， 38（9）： 796-813.

陈亮，景姗，孙蓓，等. 健脾化瘀解毒中药复方对溃疡性结肠炎患者血清细胞因子EGF、TGF-β1及TNF-α的影响［J］.天津中医药大学学报， 2017， 36（5）： 352-355.

CHEN L，JING S，SUN B，et al. Effects of Jianpi Huayu Jiedu Prescription on serum EGF、TGF-β1and TNF-α in patients with ulcerative colitis［J］. Journal of Tianjin University of Traditional Chinese Medicine， 2017， 36（5）： 352-355.

陈亮，景姗，孙蓓，等. 健脾化瘀解毒复方对溃疡性结肠炎患者炎症因子及免疫屏障影响［J］. 辽宁中医药大学学报， 2018， 20（2）： 98-101.

CHEN L，JING S，SUN B， et al. Effects of Jianpi Huayu Jiedu Prescription on Inflammatory Cytokines and Immune Barrier in Patients with Ulcerative Colitis［J］. Journal of Liaoning University of Traditional Chinese Medicine， 2018， 20（2）： 98-101.

崔国宁，刘喜平，董俊刚，等. 溃疡性结肠炎模型建立方法研究进展［J］.今日药学， 2018， 28（4）： 280-284．

CUI G N，LIU X P，DONG J G，et al. Research progress on methods of establishing ulcerative colitis model［J］. Pharmacy Today， 2018， 28（4）： 280-284．

陈素傲，金世柱. 葡聚糖硫酸钠诱导鼠溃疡性结肠炎模型研究进展［J］. 中国比较医学杂志， 2020， 30（4）： 142-146．

CHEN S A，JIN S Z. Research progress of ulcerative colitis model induced by Glucan sodium sulfate［J］. Chinese Journal of Comparative Medicine， 2020， 30（4）： 142-146．

CHASSAING B，AITKEN J D，MALLESHAPPA M，et al. Dextran sulfate sodium （DSS）-induced colitis in mice［J］. Curr Protoc Immunol， 2024， 104： 15.25.1-15.25.14.

SHAH Y M. The role of hypoxia in intestinal inflammation［J］. Mol Cell Pediatr， 2016， 3（1）： 1.

MURANO M，MAEMURA K，HIRATA I， et al. Therapeutic effect of intracolonically administered nuclear factor kappa B （p65） antisense oligonucleotide on mouse dextran sulphate sodium （DSS）-induced colitis［J］. Clin Exp Immunol， 2000， 120： 51-58.

DIELEMAN L A，RIDWAN B U，TENNYSON G S， et al. Dextran sulfate sodiuminduced colitis occurs in severe combined immunodeficient mied［J］. Gastroenterology， 1994， 107（6）： 1643-1652.

FEUERSTEIN J D，CHEIFETZ A S. Ulcerative colitis： epideminlogy，diagnosis，and management［J］. Mayo Clinic Proceedings， 2014， 89（11）： 1553-1563.

GLASSNER K L，ABRAHAM B P，QUIGLEY E M. The microbiome and inflammatory bowel disease［J］. J Allergy Clin Immunol， 2020， 145（1）： 16-27.

UNGARO R， MEHANDRU S， ALLEN P B， et al. Ulcerative colitis［J］. Lancet， 2017， 389（10080）： 1756.

张声生，沈洪，郑凯，等. 溃疡性结肠炎中医诊疗专家共识意见（2017）［J］. 中华中医药杂志， 2017， 32（8）： 3585-3589.

ZHANG S S，SHEN H，ZHENG K，et al. Expert consensus on TCM diagnosis and treatment of ulcerative colitis （2017）［J］.China Journal of Traditional Chinese Medicine and Pharmacy，2017，32（8）：3585-3589.

谢晶日，孙涛，张冰. 溃疡性结肠炎的中医药治疗进展及相关优势探讨［J］. 辽宁中医杂志， 2016， 43（2）： 425-427.

XIE J R，SUN T，ZHANG B. Progress in the treatment of ulcerative colitis with traditional Chinese medicine and discussion on its related advantages［J］. Liaoning Journal of Traditional Chinese Medicine， 2016， 43（2）： 425-427.

WANG C，TANG X，ZHANG L. Huangqin-tang and Ingredients in Modulating the Pathogenesis of ulcerative colitis［J］. Evid Based Complement Alternat Med， 2017， 2017： 7016468.

ZHENG L，ZHANG Y L，DAI Y C，et al. Jianpi Qingchang decotion aliiebiates ulcerative colitis by inhibiting nuclear factor-κB activation［J］. World J Gastroenterol， 2017， 23（7）： 1180-1188.

赵亚娇，李楠. IL-6/STAT3信号通路在溃疡性结肠炎治疗中的新进展［J］.中华消化病与影像杂志（电子版）， 2015，5（4）： 45-48.

ZHAO Y J，LI N. Progress of IL-6 /STAT3 signaling pathway in the treatment of ulcerative colitis［J］. Chinese Journal of Digestion and Medical Imageology （Election Editon）， 2015， 5（4）： 45-48.

KARAGOZ E，TANOGLU A. Clinical importance of serum procalcitonin in ulcerative colitis patients［J］. World Journal of Gastroenterolog， 2014， 20（42）： 15941-15942.

MITSUYAMA K，TOYONAGA A，SASAKI E，et al. Soluble interleukin-6 receptors in inflammatory bowel disease：relation to circulating interleukin-6［J］. Gut， 1995， 369（1）： 45-49.

王猛，王启之. 溃疡性结肠炎抗TNF-α单抗治疗的最新进展［J］. 胃肠病学和肝病学杂志， 2016， 25（4）： 468-471.

WANG M，WANG Q Z. New progress of anti-TNF-α in the treatment of ulcerative colitis［J］. Chinese Journal of Gastroenterology and Hepatology， 2016， 25（4）： 468-471.

GHAVIDEL A. Ulcerative colitis associated with aplastic anemia；a case report［J］. Middle East J Dig Dis， 2013， 5（4）： 230-234.

沈凤，李德中. IL-10基因多态性与溃疡性结肠炎易感性的关系及对临床预后的影响［J］. 中国免疫学杂志， 2016， 32（9）： 1369-1373.

SHEN F，LI D Z. IL-10 gene polymorphism with ulcerative colitis susceptibility and its influence on clinical outcomes［J］. Chinese Journal of Immunology， 2016， 32（9）： 1369-1373.

更多指标>

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Understanding， diagnosis and treatment of ulcerative colitis with Chinese and western medicine

Berberine improves ulcerative colitis in mice by inhibiting JAK2/STAT3 signal pathway

Exploration on mechanism of Shaoyao Gancao Decoction in treating ulcerative colitis based on network pharmacology and in vitro cell experiments

Effects of Yiyi Fuzi Baijiang Powder on intestinal mucosal repair in mice with acute ulcerative colitis

Effects of Lichang Decoction on intestinal microecology and brain-gut peptide in rats of ulcerative colitis with syndrome of dampness stagnancy due to spleen deficiency

Related Author

GUO Xiutian

QIU Xiaojing

AN Rui

FAN Shengjie

HUANG Cheng

LIN Chuan

ZHANG Lijun

WANG Hongqing

Related Institution

Anorectal Department， Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

School of Pharmacy， Shanghai University of Traditional Chinese Medicine

Xiangshan TCM， Huangpu District

Center for Pharmaceutics Research， Shanghai Institute of Materia Medica， Chinese Academy of Sciences

Hubei University of Traditional Chinese Medicine

⁰